



**Henri A. Termeer**

**Chairman, President and Chief Executive Officer**

Henri A. Termeer was appointed president of Genzyme Corporation in 1983, two years after the company's founding. He became its chief executive officer in 1985 and chairman in 1988. Under his leadership, Genzyme has grown from a modest entrepreneurial venture to one of the world's leading biotechnology companies.

Genzyme develops, manufactures and markets a range of innovative health care products and services that make a major positive impact on the lives of patients around the world. Genzyme's more than 10,000 employees serve patients in nearly 90 countries, and the company's 2007 revenues were \$3.8 billion. Genzyme has delivered consistent financial results, with a compound annual growth rate in excess of 20 percent over the past five years. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. Mr. Termeer is recognized as a pioneer in developing and delivering treatments to patients with rare genetic diseases around the world. This work has provided the foundation for Genzyme's success, and today the company is diversified across medical areas including lysosomal storage disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing.

Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer is active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care. He serves on the board of directors of both the Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America. He is a director of Massachusetts General Hospital and is a member of the board of fellows of Harvard Medical School.

Mr. Termeer is deputy chairman of the Federal Reserve Bank of Boston's board of directors, chairman of the board of Medical Simulation Corp. and a board member of Abiomed Inc. In 2008, he was appointed to Massachusetts Governor Deval Patrick's Council of Economic Advisors, and he is a co-chair of the Leadership Council of the Mass. Life Sciences Collaborative. Mr. Termeer is also chairman emeritus of the New England Healthcare Institute, a nonprofit, applied research health policy organization he was instrumental in founding.

With a great dedication to improving global health, Mr. Termeer is a member of the board of directors of Project HOPE, an international nonprofit health education and humanitarian assistance organization. Through a partnership with Project HOPE, Genzyme provides life-saving treatment at no cost to patients in developing countries. In addition to working with Project HOPE, Mr. Termeer has a strong interest in finding innovative ways to address neglected diseases in the developing world.

Mr. Termeer has been recognized by several highly regarded organizations for his contributions to the health care field. In 2007, he received Ernst & Young's Master Entrepreneur Award for the role he has played in guiding the overall development of the biotech industry. The award is presented periodically to entrepreneurs who have contributed to meeting significant needs in society through the creation of successful companies and the development of new industry sectors. In 2005, Mr. Termeer was elected to Honorary Fellowship at the British Royal College of Physicians, a more than

450-year-old organization dedicated to improving health care through the promotion of high standards in medical practice. In 2003, he received the Franklin Delano Roosevelt Humanitarian Award from the March of Dimes and the Cor Vitae Award from the American Heart Association. Mr. Termeer has also been inducted as a Fellow in the American Academy of Arts and Sciences.

A native of the Netherlands, Mr. Termeer in 1999 received the Golden Door Award from the International Institute of Boston, which recognizes the positive influence that immigrants have had on America. In 1995, Mr. Termeer was honored by the Anti-Defamation League's New England Region with the Torch of Liberty Award for his leadership in human rights and for promoting understanding among people of diverse religious, ethnic and racial backgrounds.

Mr. Termeer holds a strong regard for promoting education at all levels. In recognition of Genzyme's support for its educational initiatives, the Cambridge School Volunteers in 2006 selected Mr. Termeer as a representative of the organization's future and honored him for his leadership. Cambridge School Volunteers recruits, trains and supports volunteers who tutor and mentor students in Cambridge's public schools. In 2005, Mr. Termeer was recognized by the Action Center for Educational Services and Scholarships, which honors individuals and organizations committed to providing educational opportunities to Boston's youth. The Cardinal Cushing School for Exceptional Children named Mr. Termeer Humanitarian of the Year in 1997.

Mr. Termeer is a trustee for the Boston Museum of Science, and a director of the Biomedical Science Careers Program, which provides minority students with the support and guidance needed for successful careers in biomedical science. At the Massachusetts Institute of Technology, Mr. Termeer is a member of the Alfred P. Sloan Management Society. He is also a member of the board of MIT Corporation.

Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden School at the University of Virginia.



**Mark R. Bamforth**  
**Senior Vice President, Corporate Operations and**  
**Pharmaceuticals**

Mark Bamforth joined Genzyme in 1988. He is responsible for Genzyme's global manufacturing operations and strategic capacity planning as well as the Pharmaceuticals business. Prior to 2000, Mr. Bamforth ran Genzyme's United Kingdom operations. Before joining Genzyme, Mr. Bamforth worked as a drilling engineer in the North Sea offshore oil industry and then as a chemical engineer in the whisky industry in Scotland. Mr. Bamforth has an M.B.A. from Henley Business School and a B.Sc. Honours in chemical engineering from Strathclyde University.



**John Butler**  
**President, Genzyme Renal**

John Butler joined Genzyme in 1997 as product manager for Renagel. His current responsibilities include managing all aspects of the company's renal business, including Renagel, Renvela, and Hectorol, as well as managing development of the renal portfolio. He also has responsibility for the endocrinology and cardiovascular business units. Mr. Butler has also served as vice president of strategic planning and vice president of Renagel Europe. Prior to joining Genzyme, he worked in sales and marketing at Amgen Inc. Mr. Butler has an M.B.A. from Baruch College and a B.A. from Manhattan College.



**Zoltan Csimma**  
**Senior Vice President, Chief Human Resources Officer**

Zoltan Csimma joined Genzyme in 2000. He manages Genzyme's corporate human resources and security organizations, and is also responsible for developing global human resources strategies and programs. Prior to joining Genzyme, Mr. Csimma was vice president of human resources at Wyeth Ayerst Research, and vice president of human resources and operations at Genetics Institute Inc. Mr. Csimma has also worked in human resources roles for Convergent Inc., Spectra Physics Inc., and General Electric Co. He received his B.A. from the California State University at San Jose.



**Thomas J. DesRosier, Esquire**  
**Senior Vice President, General Counsel**

Thomas DesRosier joined Genzyme in 1999. He is responsible for the management of the company's legal affairs worldwide, including supervision of more than 50 internal legal professionals. Before he joined Genzyme, Mr. DesRosier was assistant general counsel for patents at American Home Products Corp., where he directed intellectual property efforts for the company's pharmaceutical products. Mr. DesRosier has also served as vice president and chief patent counsel for Genetics Institute Inc. and held several intellectual property positions at E.I. DuPont de Nemours and Company and New England Nuclear Corp. He earned a J.D. from Wake Forest University School of Law and a B.A. from the University of Vermont.



**Richard Douglas, Ph.D.**

**Senior Vice President of Corporate Development**

Richard Douglas joined Genzyme in 1989. He is responsible for evaluating and acquiring new products, programs and companies for the corporation. Dr. Douglas helps develop growth plans for Genzyme and each of its business units and subsidiaries. Prior to joining Genzyme, Dr. Douglas was director of new product development at Integrated Genetics. He has also served as the company's manager of protein chemistry research. Dr. Douglas had a post doctoral fellowship at the California Institute of Technology and received his Ph.D. in biochemistry from the University of California, Berkeley. He also has a B.S. from the University of Michigan.



**Mark J. Enyedy**

**President, Genzyme Oncology**

Mark Enyedy joined Genzyme in 1996. He is responsible for day-to-day management and strategic planning for the product portfolio of Genzyme's cancer therapeutics business unit and for the company's multiple sclerosis program. He is also responsible for managing the unit's mergers and acquisitions, product acquisition and corporate partnering transactions.

Before joining Genzyme, Mr. Enyedy practiced law at Palmer & Dodge, a Boston law firm, where he represented a number of clients in the biopharmaceutical industry in acquisition, partnering and financing transactions.

Mr. Enyedy received a J.D. from Harvard Law School and a B.S. from Northeastern University.



**David D. Fleming**

**Group Senior Vice President**

David Fleming joined Genzyme in 1984. He oversees worldwide operations and distribution for the Genzyme Diagnostics business unit. He is also responsible for corporate initiatives including e-business strategy, payment and health care delivery policy and Medicare reform. Prior to Genzyme, Mr. Fleming held general management, sales and marketing positions during 11 years at Baxter International with an emphasis on diagnostics, therapeutics and international business development. He began his career as a high school teacher. Mr. Fleming has an M.B.A. from Pepperdine University and a B.A. from the College of Wooster.



**James A. Geraghty**  
**Senior Vice President**

James Geraghty joined Genzyme in 1992. He is responsible for corporate development, product acquisition and partnering transactions. He led Genzyme's recent licensing deal with Isis Pharmaceuticals and the acquisition of SangStat Medical Corporation in 2003. He oversaw the commercialization of Cholestagel in Europe and has served as president of Genzyme Europe.

Prior to joining Genzyme, Mr. Geraghty was vice president of marketing and strategic planning for Baxter/Caremark International. He has also worked as a consultant on international health care strategy at Bain and Company.

Mr. Geraghty has a J.D. from Yale Law School, an M.S. from the University of Pennsylvania and a B.A. from Georgetown University.



**James Kean**  
**Vice President and Corporate Controller**

James Kean joined Genzyme in 1999. He has worldwide responsibility for all controllership functions, including SEC filings, accounting policies and Sarbanes Oxley compliance. Prior to joining Genzyme, Mr. Kean served as Corporate Controller for Sovereign Hill Software Inc. and Mangosoft, Inc. He also held a variety of roles at Lotus Development Corporation. Mr. Kean has an M.S. in Accounting from Bentley College and a B.S. in Chemical Engineering from the University of Massachusetts, Amherst.



**Alison Lawton**  
**Senior Vice President, Global Product Access**

Alison Lawton joined Genzyme in 1991. She has held various positions in Genzyme's regulatory affairs department since she began with the company as an international regulatory affairs specialist. In her current role, Ms. Lawton is responsible for all of Genzyme's global regulatory activities across a broad range of products. Her responsibility for global policy programs at Genzyme includes the promotion of global positions on government policies relating to public health, regulatory frameworks, and market forces. Her global health outcomes and strategic pricing group is responsible for developing health outcome and economic data to demonstrate the value of Genzyme products in the marketplace. Before coming to Genzyme, Ms. Lawton worked for seven years at Parke-Davis in the U.K. She has a B.S. from the University of London.



**Roger W. Louis, Esquire**  
**Vice President, Healthcare and Regulatory Counsel; Chief Compliance Officer**

Roger Louis joined Genzyme in 1997. He is responsible for the company's corporate compliance program and is the managing counsel for compliance and health. Prior to joining Genzyme, Mr. Louis was corporate, strategic and finance chief counsel for Blue Cross and Blue Shield of Massachusetts. He has also worked as an associate in the corporate and securities department at Hale and Dorr. Mr. Louis has a J.D. from the University of Chicago School of Law and a B.A. from Tufts University.



**Mary McGrane**  
**Senior Vice President, Government Relations**

Mary McGrane joined Genzyme in 1999. She focuses on issues and legislation of specific concern to Genzyme, including Medicare, Medicaid, orphan drugs and the Food and Drug Administration. Prior to joining Genzyme, Ms. McGrane headed the Government Relations Department at Rhone-Poulenc Rorer Pharmaceuticals Inc. Before taking that position, she had spent 12 years on Capitol Hill. During eight of those years she was a staff member of the House Committee on Energy and Commerce, serving at various times as either Minority or Majority Counsel. Ms. McGrane has a J.D. from Catholic University School of Law and a M.A. from Drew University.



**John McPherson, Ph.D.**  
**Senior Vice President, Cell and Protein R&D**

John McPherson joined Genzyme in 1989. He directs scientific research programs focused on development and commercialization of cell and protein-based therapeutic products. Before he came to Genzyme, Dr. McPherson was director of protein chemistry at Integrated Genetics. He also worked for Collagen Corporation, and was research project leader for their soft tissue wound healing program. Dr. McPherson had a post-doctoral fellowship at the University of Washington School of Medicine. He has a Ph.D. in biochemistry from the University of California, Davis. He also has a M.A. from the University of California, Davis and a B.A. from the University of California, Berkeley.



**David Meeker, M.D.**

**Executive Vice President, Therapeutics, Biosurgery & Corporate Operations**

David P. Meeker is Executive Vice President at Genzyme, overseeing the company's Therapeutics and Biosurgery business units and Global Corporate Operations. As part of this role, he is responsible for managing Genzyme's Global Manufacturing and Supply as well as Quality.

Prior to joining Genzyme in 1994, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University.

Dr. Meeker attended Dartmouth College and received his M.D. from the University of Vermont Medical School.



**Ann Merrifield**

**President, Genzyme Biosurgery**

Ann Merrifield joined Genzyme in 1992. She is responsible for managing all aspects of the orthopaedics and biosurgical specialties business units of Genzyme Biosurgery, including Synvisc and all other biomaterials products. Ms. Merrifield has also served as president of Genzyme Genetics. Prior to joining Genzyme, she was a partner at Bain and Company and an investment analyst for Aetna Life and Casualty. Ms. Merrifield has an M.B.A. from the Tuck School at Dartmouth College and a B.A. and M.Ed. from the University of Maine.



**Richard A. Moscicki, M.D.**

**Senior Vice President, Medical, Clinical and Regulatory Affairs;  
Chief Medical Officer**

Richard Moscicki joined Genzyme in 1992. He has worldwide responsibility for all aspects of clinical research, medical decisions, pharmacovigilance and regulatory. Before joining Genzyme, Dr. Moscicki was chief of immunology and allergy at Massachusetts Eye and Ear Infirmary, where he continues to work as a consultant. He also served as a staff member of Massachusetts General Hospital and has been a faculty member at Harvard Medical School since 1979. Dr. Moscicki earned his B.S. and M.D. from Northwestern University.



**Donald E. Pogorzelski**  
**President, Genzyme Diagnostics**

Donald Pogorzelski joined Genzyme in 1988. He is responsible for managing all aspects of the worldwide diagnostics business unit, including Genzyme Virotech in Russelsheim, Germany, the rapid test products in San Diego, California, and facilities in Kent, United Kingdom, and Cambridge, Massachusetts. Mr. Pogorzelski's initial responsibility at Genzyme was sales and marketing for raw materials for the domestic clinical chemistry market. Prior to joining Genzyme, he held positions in human resources, finance, and sales and marketing at Abbott Laboratories. Mr. Pogorzelski has an M.B.A. from the University of Chicago and a B.S. from Loyola University of Chicago.



**Alan E. Smith, Ph.D.**  
**Senior Vice President, Research; Chief Scientific Officer**

Alan Smith joined Genzyme in 1989. He has overall responsibility for the company's science. Before Integrated Genetics was acquired by Genzyme in 1989, Dr. Smith was that company's vice president and scientific director. Prior to joining Integrated Genetics, he was head of the Biochemistry Division of the National Institute for Medical Research, Mill Hill, in London. Dr. Smith has also served as a member of the scientific staff at London's Imperial Cancer Research Fund. Dr. Smith has a Ph.D. from the Laboratory of Molecular Biology, Cambridge, England and a B.A. from Christ's College, Cambridge, England.



**Sanford D. Smith**  
**President, International Group**

Sanford Smith joined Genzyme in 1996. He is responsible for all of Genzyme's commercial activities for the lysosomal storage disorder, renal, transplant and biosurgery products outside of the United States. Mr. Smith served as vice president and general manager of Genzyme International and president of Genzyme Specialty Therapeutics before being named to his current position in 1998. Prior to joining Genzyme, Mr. Smith was president and chief executive officer at Repligen Corporation. He has also served as vice president of business development and strategic planning for Bristol-Myers Squibb Company. Mr. Smith has a B.A. from the University of Denver.



**Gail F. Sullivan**  
**Vice President and Treasurer**

Gail Sullivan joined Genzyme in 2007. She is responsible for Genzyme's global treasury operations, including corporate financing, cash management, risk management, and investment management. Prior to joining Genzyme, Ms. Sullivan was vice president and treasurer of The Gillette Company. She has also held various managerial and financial positions at Gillette and at Digital Equipment Corporation.

Ms. Sullivan has an M.B.A. from the Tuck School of Business at Dartmouth and a B.A. from Dartmouth College.



**Peter Wirth, Esquire**  
**Executive Vice President, Legal and Corporate Development;**  
**Chief Legal Officer; Secretary**

Peter Wirth joined Genzyme in 1996 after having served as the company's outside general counsel since 1982. He has senior management responsibility for the corporate development and legal departments. Prior to joining Genzyme, he was a partner at Palmer and Dodge, a Boston law firm, where he was head of the firm's technology group. Mr. Wirth has a J.D. from Harvard Law School and a B.A. from the University of Wisconsin.



**Michael S. Wyzga**  
**Executive Vice President, Finance; Chief Financial and**  
**Accounting Officer**

Michael Wyzga joined Genzyme in 1998, and is responsible for global financial reporting. Prior to joining Genzyme, Mr. Wyzga was chief financial officer of Sovereign Hill Software Inc. He also served as vice president of finance and chief financial officer of CacheLink Corporation, a client/service software company. Mr. Wyzga has also held management positions at both Lotus Development Corporation and Digital Equipment Corporation. Mr. Wyzga has an M.B.A. from Providence College and a B.S. from Suffolk University.